Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy

Clinical and Experimental Allergy

Volumn 36, Issue 6, 2006, Pages 704-713

  Mamessier, E ^a   Birnbaum, J ^a,b   Dupuy, P ^c   Vervloet, D ^a   Magnan, A ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c INSERM   (France)

Author keywords

Immunotherapy; Regulatory T cells; T lymphocytes; Th1 to Th2 switch; Vespid venom

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; HYMENOPTERA VENOM; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; WASP VENOM;

ADULT; ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; BLOOD SAMPLING; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HELPER CELL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INSECT ALLERGY; INTERFERON PRODUCTION; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANALYSIS OF VARIANCE; DESENSITIZATION, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; INTERLEUKIN-4; LINEAR MODELS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY; WASP VENOMS;

EID: 33745666983     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2006.02487.x     Document Type: Article

References (40)

1. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996; 97:579-87.
2. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:1025-34.
3. Houliston L, Brookes I, Mallon DF. Venom immunotherapy. N Engl J Med 2004; 351:2129-30.
4. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154:4187-94.
5. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997; 27:1131-9.
6. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102:98-106.
7. Kapsenberg ML, Hilkens CM, Wierenga EA, Kalinski P. The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy. Clin Exp Allergy 1999; 29 (Suppl. 2):33-6.
8. Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101:747-54.
9. Akdis CA, Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J 1999; 13:603-9.
10. Bellinghausen I, Knop J, Saloga J. The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol 2001; 126:97-101.
11. Gardner LM, Thien FC, Douglass JA, Rolland JM, O'Hehir RE. Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy 2004; 34:1209-19.
12. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205-14.
13. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10:801-5.
14. Brown SG, Haas MA, Black JA, Parameswaran A, Woods GM, Meddle RJ. In vitro testing to diagnose venom allergy and monitor immunotherapy: a placebo-controlled, crossover trial. Clin Exp Allergy 2004; 34:792-800.
15. Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966; 3:331-3.
16. Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993; 23:226-30.
17. Richter A, Lohning M, Radbruch A. Instruction for cytokine expression in T helper lymphocytes in relation to proliferation and cell cycle progression. J Exp Med 1999; 190:1439-50.
18. + T cells from allergic individuals. J Exp Med 1993; 178:2123-30.
19. McHugh S, Deighton J, Rifkin I, Ewan P. Kinetics and functional implications of Th1 and Th2 cytokine production following activation of peripheral blood mononuclear cells in primary culture. Eur J Immunol 1996; 26:1260-5.
20. Akoum H, Tsicopoulos A, Vorng H et al. Venom immunotherapy modulates interleukin-4 and interferon-gamma messenger RNA expression of peripheral T lymphocytes. Immunology 1996; 87:593-8.
21. Jutel M, Wyss-Coray T, Carballido JM, Blaser K, Muller UR, Pichler WJ. Selective restimulation of antigen or allergen pre-activated T cells using OKT3 F(ab)2 results in the secretion of TH-1 or TH-2-like cytokine patterns. Clin Exp Allergy 1995; 25:1108-17.
22. Pierkes M, Bellinghausen I, Hultsch T, Metz G, Knop J, Saloga J. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after vespid venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol 1999; 103:326-32.
23. Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004; 112:352-63.
24. Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005; 2:e78.
25. Schuerwegh AJ, De Clerck LS, Bridts CH, Stevens WJ. Vespid venom immunotherapy induces a shift from IL-4-producing towards interferon-gamma- producing CD4+ and CD8+ T lymphocytes. Clin Exp Allergy 2001; 31:740-6.
26. Bellinghausen I, Klostermann B, Bottcher I, Knop J, Saloga J. Importance of the inducible costimulator molecule for the induction of allergic immune responses and its decreased expression on T helper cells after venom immunotherapy. Immunology 2004; 112:80-6.
27. Nasser SM, Ying S, Meng Q, Kay AB, Ewan PW. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing vespid venom immunotherapy. Eur J Immunol 2001; 31:3704-13.
28. Segura JA, Assenmacher M, Irsch J, Hunzelmann N, Radbruch A. Systemic T-cell unresponsiveness during rush bee-venom immunotherapy. Allergy 1998; 53:233-40.
29. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995; 25:828-38.
30. Secrist H, DeKruyff RH, Umetsu DT. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995; 181:1081-9.
31. Akdis M, Verhagen J, Taylor A et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199:1567-75.
32. Ling EM, Smith T, Nguyen XD et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363:608-15.
33. Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med 2004; 199:1679-88.
34. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+ CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255-61.
35. 5 Nakamura K, Kitani A, Fuss I et al. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004; 172:834-42.
36. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192:295-302.
37. Akoum H, Duez C, Vorng H et al. Early modifications of chemokine production and mRNA expression during rush venom immunotherapy. Cytokine 1998; 10:706-12.
38. Magnan A, Marin V, Mely L et al. Venom immunotherapy induces monocyte activation. Clin Exp Allergy 2001; 31:1303-9.
39. Des Roches A, Paradis L, Knani J et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51:430-3.
40. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000; 55:842-9.